RT Journal Article
T1 Treatment with the senolytics dasatinib/quercetin reduces SARS‐CoV‐2‐related mortality in mice
A1 Pastor Fernández, Andrés
A1 Sierra Ramírez, Arantzazu
A1 del Moral Salmoral, Javier
A1 Merino, Javier
A1 de Ávila, Ana I.
A1 Olagüe, Cristina
A1 Villares, Ricardo
A1 González Aseguinolaza, Gloria
A1 Rodríguez, María Ángeles
A1 Fresno, Manuel
A1 Gironés, Nuria
A1 Bustos, Matilde
A1 Smerdou, Cristian
A1 Fernandez Marcos, Pablo Jose
A1 von Kobbe, Cayetano
A1 Rodríguez Bertos, Antonio Manuel
AB The enormous societal impact of the ongoing COVID‐19 pandemic has been particularly harsh for some social groups, such as the elderly. Recently, it has been suggested that senescent cells could play a central role in pathogenesis by exacerbating the pro‐inflammatory immune response against SARS‐CoV‐2. Therefore, the selective clearance of senescent cells by senolytic drugs may be useful as a therapy to ameliorate the symptoms of COVID‐19 in some cases. Using the established COVID‐19 murine model K18‐hACE2, we demonstrated that a combination of the senolytics dasatinib and quercetin (D/Q) significantly reduced SARS‐CoV‐2‐related mortality, delayed its onset, and reduced the number of other clinical symptoms. The increase in senescent markers that we detected in the lungs in response to SARS‐CoV‐2 may be related to the post‐COVID‐19 sequelae described to date. These results place senescent cells as central targets for the treatment of COVID‐19, and make D/Q a new and promising therapeutic tool.
PB Wiley
SN 1474-9718
SN 1474-9726
YR 2023
FD 2023-01-26
LK https://hdl.handle.net/20.500.14352/107558
UL https://hdl.handle.net/20.500.14352/107558
LA eng
NO Pastor-Fernández, A., Bertos, A. R., Sierra-Ramírez, A., Del Moral-Salmoral, J., Merino, J., de Ávila, A. I., Olagüe, C., Villares, R., González-Aseguinolaza, G., Rodríguez, M. Á., Fresno, M., Gironés, N., Bustos, M., Smerdou, C., Fernandez-Marcos, P. J., & von Kobbe, C. (2023). Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice. Aging cell, 22(3), e13771. https://doi.org/10.1111/acel.13771
NO AU T H O R CO N T R I B U T I O N S: Design the project (R.V., M.F., N.G., M.B., C.S., P.J.F.M., and C.V.K.);Performance of experiments (A.P., A.R.B., A.S.R., J.M.S., J.M.,A.I.d.Á., C.O., and M.A.R.); Data analysis (A.P., A.R.B., A.S.R., G.G.A.,M.B., C.S., P.J.F.M., and C.V.K.); Wrote the manuscript (C.V.K.).DATA AVA I L A B I L I T Y S TAT E M E N TThe data that support the findings of this study are available fromthe corresponding author upon reasonable request.
NO Instituto de Salud Carlos III
NO Ministerio de Ciencia, Innovación y Universidades
NO AECC ScientificFoundation
NO SIRTBIO
NO European Union
NO Consejo Superior de Investigaciones Científicas
DS Docta Complutense
RD 10 abr 2025